GS Chain, a company established with the purpose of undertaking acquisitions of an interest in an operating company or business in the technology sector, intends to list on the Main Market (Standard). Timing TBC.
Altona Rare Earths, the AQSE listed mining exploration Company focused on the evaluation, acquisition and development of Rare Earth Elements mining projects in Africa, intends to join the Main Market. Admission to trading of the Company’s Ordinary Shares on the AQSE Growth Market will be cancelled simultaneously with Admission. It is also proposed that on Admission, the Company will change its EPIC from AQSE:ANR to REE. The Company also seeks to raise funds to finance its current and future rare earths mining projects in Southern and Eastern Africa. Due May 2022.
AEX Gold 44.5p £85.5m (AEXG.L)
Announced results of its 2021 exploration campaign across the Vagar licence, South Greenland. The exploration results more than double the Vagar Ridge footprint, confirming its potential to be a multi-million ounce prospect. As a result of the 2021 exploration results, AEX believes that Vagar Ridge may host up to 4 Orogenic gold veins with new rock chip samples giving up to 86.7 g/t gold. The 2021 program included hyperspectral imaging, reconnaissance sampling and a 385 km2 high resolution airborne magnetic survey, interpreted by SRK Consulting, which has defined a significant deformation zone which extends for more than 50km across the licence and into AEX’s neighbouring licences, highlighting 5 priority targets. Vagar Ridge was historically sampled and drilled across 2km discovering up to 2,533 g/t gold in vein material and 13m at 70.1 g/t gold from follow up channel sampling and a core drilling program. It also identified granodiorite-hosted mineralisation up to 14.4 g/t gold, opening up the potential for a large scale Intrusion Related Gold mineralisation. 2021 results confirmed gold mineralisation within the host rock, verifying the presence of widespread granodiorite-hosted mineralisation including 9.25 g/t gold in scree samples from a previously unexplored northern target. Ground-based hyperspectral imaging, a powerful tool for areas with limited vegetation such as in Southern Greenland, is proving to be an effective method for identifying hydrothermal alteration and altered granodiorite, the preferential host of both Orogenic and Intrusion Related Gold mineralisation in the Vagar licence.
Amur Minerals 1.9p £26.5m (AMC.L)
The nickel-copper sulphide mineral exploration and resource development company focused on the far east of Russia, announces that it, together with its wholly owned subsidiary Irosta Trading Limited, has entered into a Share Purchase Agreement) for the sale of 100% of its interest in Irosta’s wholly owned subsidiary, AO Kun-Manie (AO KM or Kun-Manie). For a total consideration of US$105m, Stanmix Holding Limited will purchase AO KM and the benefit of all amounts owed by AO KM to Amur under intra-group loans (the Transaction). AO KM is an exploration and mining company which holds the Detailed Exploration and Mine Production mineral licence for the Kun-Manie nickel-copper sulphide project located in Amur Oblast of the Russian Federation.
Clontarf Energy 0.5p £11.2m (CLON.L)
The Company has acquired a 10% interest in the high-impact multi-TCF (Trillion Cubic Feet) Sasanof exploration prospect (located mainly within Exploration Permit WA-519-P) through the acquisition of a 10% interest in Western Gas (519 P) Pty Ltd (WG519P), which wholly owns the prospect; plans to drill the main target horizon (the Sasanof-1 Well) in this prospect during May/June 2022; the Acquisition consideration will be comprised of a cash consideration of US$4m and 100,000,000 ordinary shares of 0.25p each, valued at £480k as at May 6th close. In the event of a discovery being declared at the Sasanof-1 Well, the consideration will be further increased by 150,000,000 Ordinary Shares, up to a maximum of £8.7m.
Cora Gold 7.35p £21.28m (CORA.L)
The first drill results from its 2022 drill programme at the Company’s Sanankoro Gold Project in southern Mali. Drill programme consisting of 11 aircore (AC) shallow holes for 897m and 78 reverse circulation (RC) holes for a total of 6,992m (4,958m at Zone B North; 1,092m at Selin South, 504m at Fode 1 and 438m at Target 6) now completed at Sanankoro. Drilling targeted both converting existing Inferred Mineral Resources to Indicated Mineral Resources, as well as identifying new discoveries at Sanankoro. RC drill highlights at Zone B North: 25m @ 2.38 g/t Au from 65m in hole SC0595; 27m @ 1.40 g/t Au from 18m in hole SC0600; 5m @ 4.64 g/t Au from 48m in hole SC0598; 20m @ 1.09 g/t Au from 83m in hole SC0597; 8m @ 2.47 g/t Au from 39m in hole SC0593; 8m @ 1.88 g/t Au from 39m in hole SC0593; 8m @ 1.74 g/t Au from 37m in hole SC0583. Two new discoveries: Fode 1 and Target 6 both in close proximity to existing Mineral Resources. AC drill highlights: 2m @ 3.56 g/t Au from 41m in hole SC0572 at Fode 1; 6m @ 0.65 g/t Au from 66m, including 2m @ 1.62 g/t Au in hole SC0573 at Fode 1; 3m @ 1.24 g/t Au from 7m in hole SC0579 at Target 6; Awaiting results from RC follow up drill holes at these discoveries. Drill results consist of all the AC holes and the first 28 RC holes completed at Zone B North. Drill results for the later RC holes are expected imminently.
K3 Capital Group 230p £169m (K3C.L)
The multi-disciplinary professional services firm providing advisory services to SMEs, notes the recent performance of its share price and confirms that it is not aware of any reason for such a decline. In the Interim Results announcement on 7 February 2022, the Board confirmed that the outlook for the remainder of the financial year, and beyond, was positive and were pleased to report a strong start to H2 FY22. Trading since then has continued to be positive. The Board remains very confident in its outlook for the year, with all three divisions showing strong levels of activity. Recent acquisitions are performing in line with plan. The acquisition pipeline is healthy with various bolt-ons being evaluated. The Company looks forward to providing more detail in its year end trading statement in June.
Life Sciences REIT 103p £360.5m (LABS.L)
The real estate investment trust focused on UK life science properties, announces that, on 6 May 2022, it completed the acquisition of 7-11 Herbrand Street, an iconic Art Deco building close to University College Hospital and University College London in London’s Knowledge Quarter. The purchase price of £85m, excluding acquisition costs, was satisfied entirely in cash and reflects a net initial yield of 4.42% based on the underlying net passing rent of £59.85 per square foot. The entire building is currently let to Thought Machine, one of the UK’s leading fintech companies, until October 2026. The property, which currently comprises Grade A office space, totals a net internal area of 67,097 square feet on four floors with a partial basement, and represents an ideal opportunity for development as a major life science asset. It is situated in close proximity to a number of major academic institutions, healthcare organisations and innovative companies including University College London, University College Hospital, the Francis Crick Institute and the Oriel project. The property is well-located for access to Euston, King’s Cross, St Pancras and Tottenham Court Road transport hubs with Russell Square tube station just 100 metres away. Life Science REIT, has undertaken a feasibility study to determine the suitability for lab conversion. The study confirmed that the building has great potential and benefits from large floor to ceiling heights, structural slab and large, column-free floor plates.
Mincon Group 102p £223.6m (MCON.L)
The Irish engineering group specialising in the design, manufacture, sale and servicing of rock drilling tools and associated consumable products, today provides a trading update for the period from 1st January 2022 to date, incorporating the first quarter to 31st March 2022. Mincon has carried the positive revenue momentum from H2 2021 into the first quarter of 2022, while continuing to build on order books during this quarter, driven by the strong underlying demand for our products across the Construction, Mining and Waterwell/Geothermal sectors. Manufacturing remains under pressure to supply the increased demand, though Mincon has increased capacity across the Group through investment in factories and through the acquisition of Spartan Drilling Tools, a drill pipe manufacturer in the USA, in January 2022.
Nostra Terra Oil & Gas 0.63p £4.5m (NTOG.L)
The international oil & gas exploration and production company with a portfolio of production and development assets in Texas, USA, announced that the Grant East #1 well, in the Permian Basin, West Texas, has reached total depth. Following the spud announcement on the 3rd of May, the Company reports that the Grant East #1 reached a total depth of 3,200 feet on May 3, 2022, just below the Clear Fork Formation. Log analysis shows the well encountered the Upper Clear Fork at approximately 2,560 feet and the Lower Clear Fork at approximately 2,806 feet with 24 feet of gross reservoir section in the Upper Clear Fork and 108 feet of gross reservoir section in the Lower Clear Fork. This well compares favourably with the NTOG operated wells on an adjoining lease to the west (the Grant #5 and #6 wells). The well has been cased and cemented through both pay intervals. The perforations have been selected and fracture stimulation program has been designed and is scheduled to take place later this week. Construction of the tank battery has commenced. Following completion, the well is planned to be put into production. Nostra Terra owns a 100% working interest and is the operator.
Quadrise 2.19p £30.8m (QFI.L)
Presents an update following a board review of the Company’s projects, operations and business development activities. The conclusion of the board review is that the Company is on track to achieve its commercialisation targets following positive engagement with counterparties during the past month. The Company therefore intends to progress with each of its core projects as well as with the development of bioMSAR™ fuel and its derivatives. MSC: Quadrise recently met with MSC executive management in Cyprus and both parties are now working to finalise an agreement covering the LONO trial programme aboard MSC container shipping vessels and the subsequent commercial framework. The conclusion is that the Company is on track to achieve its commercialisation targets following positive engagement with counterparties during the past month. The Company intends to progress with each of its core projects as well as with the development of bioMSAR™ fuel and its derivatives. Morocco: an updated Material Transfer and Cooperation Agreement with our international chemicals and mining client is now expected to be signed this month ahead of an MSAR ® combustion trial that is expected to conclude early Q3 2022. Utah: following signing of Commercial Development Agreement in April 2022, Quadrise and Valkor have commenced preparatory steps under Phase 1 of the CDA to identify target consumers of MSAR ® and bioMSAR ™ fuel. Testing with Aquafuel this quarter will conclude the bioMSAR™ engine efficiency optimisation work, with results expected in early Q3 2022. Discussions are underway with several candidate sites in Panama and Honduras for MSAR ® and bioMSAR ™ power plant trials later in 2022.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
